Extended Data Fig. 2: Profiling of intestinal epithelium following ENU treatment.
From: Decay of driver mutations shapes the landscape of intestinal transformation
a, Immunohistochemistry (IHC) of ENU-induced O6-ethyl-2′deoxyguanosine adducts at different time-points post-ENU (no ENU control, 4 h, 24 h, and 7 days; n = 1 mouse per treatment/time-point) in proximal SI. b, Intestinal tumour count per mouse in relation to age at treatment in control (ENU) cohort (HEP, humane end point; HEP(L), presence of lymphoma/leukaemia at HEP). c, Mean (SD) intestinal tumour count per mouse in relation to median survival in tamoxifen-induced (Tam) cohorts. d, Representative β-catenin IHC in a panel of tumours from Fbxw7null(n = 97), Ptennull(n = 14), KrasG12D(n = 173), and Trp53null(n = 23) cohorts. e, Lower panel: heatmap with relative tumour burden per location in relation to cohort. Mean tumour counts displayed in each square. Upper panel: proportion of mice with distant metastases per cohort. f, Proportion of tumours with local invasion (carcinoma in situ) in relation to cohort. P-values in (f) were derived using a two-sample test of equality of proportions with continuity correction (two-sided). Scale bar = 100 μm.
